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 Abstract 
Recent studies have revealed that elevated levels of serotonin or 5HT lead to valve dysfunction. 
A mouse model was successfully established to investigate the effects on the aortic valve in 
subjects with elevated 5HT levels along with cardiovascular hypertension. For each two-week 
trial, eight C57BL/6J mice were divided into the following expermental groups: control, 5HT, 
angiotensin II, and 5HT+angiotensin II. The drug was delivered to the mice via osmotic pumps 
(Ang II: 0.4ng/g/min, 5HT:0.0025ng/g/min) or direct injections(Ang II: 0.1 mg, 5HT: 2.12 mg, 
every other day)  and the blood pressure of the mice was continually monitored via the CODA 
tail cuff system. The direct injection model was determined to be a more effective model as the 
drug delivery was more controllable and there were far less adverse events with the mice. At the 
end of two weeks, the mice were sacrificed and one heart from each group was used for western 
blotting and the other for histology. Western blotting for the 5HT2A/2B receptors, along with FGF-
1, FGF-2, FGF-R1 revealed some trends, but more trials are needed to confirm the significance 
of these trends. Future studies using this model could successfully reveal the mechanism by 
which elevated 5HT levels can lead to a diseased aortic valve when under high mechanical 
stress. 
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 1 Introduction 
1.1) Serotonin 
Serotonin or 5-hydroxytryptamine (5HT) is a neurotransmitter synthesized in the central nervous 
system.3,6 The synthesis pathway is shown below in figure (1c).There is always serotonin present 
in the human body as it is a neurotransmitter that is heavily involved in the regulation of the 
nervous and gastrointestinal systems. However, when serotonin levels drop too low, a person 
goes into clinical depression. Of particular interest to our study is the fact that serotonin has 
multiple effects on the cardiovascular system due to the numerous receptor subtypes present. 
There are 5HT receptors that control vasoconstriction and vasodilation, and others that are 
variably expressed in the valve tissues. Significantly, the aortic valve is innervated as shown by 
staining for acetylcholine in figure (1a). The presence of nerves also implies the presence of the 
neurotransmitter serotonin. Furthermore, the valve itself has 5HT receptors which certainly 
means that 5HT is present in the aortic valve. Recent studies have pointed towards 5HT as 
causing valve dysfunction if present at elevated levels.4,6,-10,12 This dysfunction results in 
pathologic conditions within the valve that can often require a valve replacement to repair.  
Another relevant fact about serotonin is that when its bodily levels drop below the normal value, 
the functions of the nervous system are negatively affected. In fact, low serotonin levels are 
associated with depression. It is not yet known whether these low serotonin levels cause 
depression or if low serotonin is a byproduct of depression. Still, doctors often prescribe 
antidepressants (Zoloft, Prozac, Lexapro, Celexa, etc.) that are selective serotonin reuptake 
inhibitors (SSRIs). These SSRIs prevent the reuptake of serotonin back into the presynaptic 
neuron, thus increasing the levels of circulating serotonin in the body. This process is depicted in 
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 figure (1b).  These drugs that result in an increased level of serotonin are believed to be a viable 
treatment for depression.  
 
 
   
 
 
 
5HT Receptor 
5HT 
SSRI 
Figure 1: (a)The image in shows an aortic valve that was stained for acetylcholine, a 
common neurotransmitter. The black lines represent the acetylcholine and thus outline the 
nerves.16 
(b) The image on the right shows the mechanism of SSRIs on 5HT pathway in the synapses 
between nerves.15 
(c) Serotonin synthesis pathway. This occurs naturally in the human body.17 
a) b) 
5HT Transporter 
c) 
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 1.2) Aortic Valves 
The aortic valve is found between the right ventricle and the aorta, the largest artery in the body. 
This valve is open in systole, allowing the flow of oxygenated blood through the aorta and to the 
rest of the body. During diastole, the valve remains closed to prevent backflow of blood from the 
aorta back into the ventricle. This is pictured below in figure (2c), which also illustrates that the 
aortic valve has three leaflets. Each leaflet or cusp of the aortic valve has three easily identifiable 
and distinguishable layers.13 These layers are the lamina fibrosa, the lamina spongiosa, and the 
lamina radialis. These layers are pictured in figure 2a and 2b. The lamina fibrosa is the widest 
layer and resides on the arterial side of the valve. This layer mostly contains densely packed 
collagen. The lamina radialis or ventricularis is the thinnest layer and borders the ventricular side 
of the valve. This layer contains the majority of the valve’s elastin as well as a significant 
amount of densely packed collagen fibers. Finally, the lamina spongiosa lies in between the 
fibrosa and the ventricularis and has a few loosely arranged collagen fibers along with most of 
the aortic valve’s glycosaminoglycans (GAGs).13 Additionally, a thin layer of valvular 
endothelial cells (VECs) covers the entire leaflet. Finally, within the extracellular matrix of each 
of the layers lie myofibroblasts and valvular interstitial cells (VICs) that are similar to smooth 
muscle cells. 
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In the bottom right panel of figure 2c, a stenotic aortic valve is shown. As defined by the Mayo 
Clinic, aortic valve stenosis occurs when the aortic valve narrows, preventing the valve from 
opening or closing fully. This reduced functionality of the valve, if untreated, can lead to serious 
heart problems or even death. In general, the only viable treatment option for severe aortic valve 
stenosis is valve replacement. Naturally, the ideal situation for a patient would be to intervene in 
the process that leads to stenosis such that a valve replacement never even needs to be 
considered.  
Significant to our study, as figure (1) shows, the aortic valve is innervated. This is important, 
because as discussed above, serotonin is a neurotransmitter. The conclusion can directly be 
drawn that serotonin is present in the valve. Additionally, it is known that there are two families 
of 5HT receptors that are abundantly present and active in the valves of the heart. The question 
a) 
b) 
c) 
Figure 2: Panels (a)18 and (b)19 show the 
layered structure of an aortic valve leaflet. 
Figure (b) is histological sample showing the 
layers. Panel (c)20 shows the placement of the 
aortic valve in the heart (left), along with the 
normal and stenotic aortic valve (right).  
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 of interest to this study is what is the effect of elevated serotonin levels on the heart valve? These 
receptors are the 5HT1B/IC and 5HT2A/2B receptors.5,11 Previous work has demonstrated that 5HT 
signaling in the aortic valve is mediated primarily by the 5HT2A and 5HT2B  receptor subtypes.2 
Recent data also shows that under elevated cyclic mechanical stretch gene expression for both 
receptor types increases.1,2 These same studies show that further elevation of mechanical stretch 
prompted signaling via the 5HT2A but not the 5HT2B receptor subtypes, suggesting that the 
5HT receptors have sensitivity that is based upon stress magnitude. This increase in stretch 
magnitude on a valve is a direct result of cardiovascular hypertension. 
 
1.3) Motivation for this Study 
As discussed, the aortic valve can become dysfunctional as a result of elevated serotonin. 
Additionally, recent studies have pointed out that the serotonin receptors on the aortic valve 
become more sensitive under increased mechanical stress or hypertension. This directly implies 
that hypertension in combination with elevated 5HT levels put a person at high risk for aortic 
valve stenosis. If the mechanism of action for this aortic valve pathology becomes well 
understood, prevention, rather than reaction would become a plausible treatment. Specifically, if 
we understood how receptor activity changed with varying cyclic stretch magnitudes, it would 
point to possibilities for targeting particular 5HT receptors for treatment depending on the 
hemodynamic stress state of the patient. This is the direct motivation for the study.  
A primary example of this in the real world was the FenPhen trial. This drug combination was an 
anti-obesity treatment that utilized two anorectics. Fenfluramine acts a serotonin releasing agent 
and phentermine acts as a norepinephrine, dopamine, and serotonin releasing agent. The problem 
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 with this drug trial was that individuals treated with this combination developed aortic 
insufficiency and valve fibrosis. Significantly, these patients also demonstrate symptoms of 
pulmonary hypertension. This example simply asserts the importance of studying the interaction 
of 5HT and heart valves due to the possible severe consequences.  
 
1.4) Objectives and Hypothesis 
There are two overall objectives for this research project. First, we want to determine the synergy 
between cyclic stretch and 5HT signaling that may potentially result in aortic valve disease and 
dysfunction. The second goal is to understand the effects of this receptor signaling on valve cell 
mechanics and functions.  
Questions to answer: 
1) Doe 5HT signaling depend on the mechanical environment of the valve? 
2) What are the immediate functional consequences of 5HT signaling in the valve? 
The hypothesis is that the aortic valve responds to elevated levels of 5HT via 
mechanosensitive 5HT synthesis, signaling, and reuptake. It is additionally hypothesized 
that the 5HT2A receptor subtype increases in responsiveness and expression with increased 
mechanical stretch.  
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 2: Methods 
2.1) General 
One of the main objectives for my personal project was to set up an animal model that would 
allow for testing of the hypotheses in a biological system. Female C57BL/6J mice were chosen 
as the animal for our study and ordered from the Jackson Laboratory. These animals were chosen 
because hypertension models were available and knockouts were available for purchase if 
necessary. Additionally, low cost and a mouse facility that was near the lab made mice a good 
choice. The mice were housed and maintained under pathogen-free conditions in microisolator 
cages. The Institutional Animal Care and Use Committee at the University of Arkansas approved 
all experimental procedures.  
In order to generate an animal model that generated heart valves exposed to high serotonin levels 
at high degrees of mechanical stretch, several drugs for treatment of the mice were necessary. 
First, to increase the serotonin levels, serotonin was administered directly to the mice. This is the 
easiest and most efficient way to expose the mice to elevated serotonin levels in the body. To 
achieve high mechanical stress on the valve, a hypertensive environment needed to be 
established. Angiotensin II was our drug of choice for creating the high blood pressure. 
Angiotensin II is a hormone that plays a central role in cardiovascular homeostasis.14 It is a 
vasoconstrictor and has been shown to play important roles in mediating hypertension, heart 
failure, and cardiac remodeling. 
Upon arrival, the powder form of these drugs was dissolved in the appropriate amount of filter-
sterilized saline solution to create a stock solution. These stock solutions were generally at 0.1M 
for the serotonin and 0.01M for the angiotensin II. These stock solutions were divided into 1mL 
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 aliquots which were frozen in the -20°C freezer. When the drugs were needed for treatment of 
the mice, the frozen drug was diluted to the appropriate concentration.  
 
2.2) Blood Pressure Analysis 
For the animal model, it was essential to monitor the blood pressures of the animals in order to 
ensure that the aortic valves had been subjected to the high mechanical stress that is associated 
with hypertension. Through literature research, it was determined that the best way to monitor 
the blood pressure of the mice in short term experiments was using a volume pressure recording 
tail cuff method. This method is a clinically validated technique used to measure the blood 
pressure in mice and rats according to the Kent Scientific Website. The principle behind the tail 
cuff method of blood pressure measurement is very similar to the arm cuffs that are commonly 
used on humans. As seen in figure (3b) the tail cuff system is comprised of two separate cuffs 
that are placed on the tail. The O-cuff is the smaller, circular cuff that is pushed up right next to 
the body of the mouse, while the VPR cuff is the longer cuff that goes on the tail of the mouse 
distal to the O-cuff. At the beginning of each cycle, the VPR cuff pushes the blood out of the tail 
and then the O-cuff inflates to prevent the flow of blood back into the tail. Similar to the human 
arm cuff, the O-cuff slowly deflates as the measurement is taken. When the O-cuff deflates to a 
pressure equivalent to the systolic blood pressure, blood begins to flow back into the tail, thus 
increasing the tail volume. This first increase in tail volume is recorded as the systolic blood 
pressure as the mouse. As the O-cuff continues to deflate, the blood flow into and out of the tail 
will eventually equalize. The pressure at which this occurs is recorded as the diastolic blood 
pressure. Research suggests that the systolic blood pressure of the VPR tail cuff method is 
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 generally more accurate since the initial increase in volume is more easily detected than the point 
at which the volume equalizes.   
 
The CODA Standard Non-Invasive Blood Pressure System produced by Kent Scientific was 
purchased for use in the mouse experiments. This system consisted of tail cuffs, a warming 
platform, a CODA controller, and two rodent holders as pictured in figure (3). We additionally 
ordered two extra rodent holders to make the process more efficient and accurate. 
 
 
The blood pressure of each animal was routinely measured throughout each of the animal trials. 
The procedure involved placing the mice in the animal holders, placing the tail cuff device on the 
tail of the device, and utilizing the CODA software to take the blood pressure measurement. In 
our particular study, we used 5 acclimation cycles and 10 regular cycles for each animal in order 
to gather sufficient data to ensure accurate pressure readings.  
Figure 3: (a) Components of the CODA Standard blood pressure analysis system.21 
(b) VPR and O Cuffs21 
a) 
b) 
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 After the data had been collected from the tail cuff system, it was exported to excel in for 
processing. The tail cuff system determined if each cycle demonstrated an “accepted” or 
“rejected” reading. The rejected readings and acclimation cycle pressures were removed from the 
data set. Next the average of the remaining systolic and diastolic pressures were calculated and 
plotted in a graph. Additionally, the standard deviation of the blood pressure readings was 
calculated and added to the graph. 
The complete and detailed protocol for usage of the CODA tail cuff system is in appendix A.  
2.3) Osmotic Pumps 
One method that was used to administer the drugs to the mice was osmotic pump implantation. 
Alzet osmotic pumps (model 1004, 2004) were used for this method of drug administration. The 
osmotic pumps simply utilize principles of diffusion to deliver the drug solution that they are 
filled with. The rate at which the pump delivers the solution within the pump is constant and 
depends on the model of pump that is purchased. For this reason, the only way to control the 
time release rate of the drug is to vary the concentration of the drug solution that is injected into 
the micro osmotic pumps prior to implantation into the animal.   
Gathering knowledge from previous published studies, particularly from our collaborator Dr. 
Kilic of UAMS, we decided to administer angiotensin II and serotonin at 0.4ng/g/min, 
5HT:0.0025ng/g/min respectively. Knowing the rate of diffusion from the pump, the reservoir 
volume of the pump, and the desired duration of the trial, we were able to fill the pumps with the 
correct concentration of each drug to administer it at the rate that we desired.  
After calculating the necessary drug concentration, solutions containing these concentrations of 
drug were created and used to fill the pumps with the solutions. Following the filling of the 
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 pumps, the pumps were placed in saline solution and incubated at 37 degrees celsius in order to 
prime the pump. This was simply done to ensure that the pump was already actively pumping the 
correct amount of drug upon implantion into the mice.  
Next was the actual implantation of the pumps into the mice. First, the mice had to be 
anesthetized with 100uL of a 1:1:4.6  ketamine/xylene/ddH2O solution. This amount could vary 
slightly depending on the reactions of the mice to the drug, which depended on the weight and 
size of the mouse. The mice were shaved at the site of implation and an incision was made that 
was just large enough to insert the pump. This incision was always made just above and a bit 
posterior to one of the front shoulders of the mouse. A subcutaneous pocket was then gently 
opened up with small surgical scissors. The pump was next slid into the prepared pocket in the 
subcutaneous layer and the incision was closed with stainless steel surgical clips from a the 
Reflex skin closure system 9. After this, the mice were left on a heating pad until they began to 
regain consciousness. The surgical procedure was very short and efficient, only taking around 5-
10 minutes for each mouse.  
2.4) Injection Trials 
Besides osmotic pumps, the method of direct injections was explored as an alternative drug 
delivery method for the mouse model. The purpose exploring this drug delivery method was to 
reduce the complexity of the model and to ensure that the desired amount of drug was delivered 
to the mouse each day. Literature was consulted to determine the ideal amounts of 5HT and 
angiotensin II to include in each injection. It was decided that 2.12 mg of 5HT would be injected 
every other day, but an ideal amount of angiotensin II for each injection was not found. 
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 However, knowing the suggested amount of angiotensin II used for the osmotic pumps allowed 
for calculation of an approximate daily value of delivered angiotensin II.  
The injection trial to determine the optimal amount of aniotensin II delivered in the injections 
consisted of two experimental groups of three mice each. One group was injected every other 
day with 10ug of aniotensin II and the other group was injected every other day with 100 ug of 
angiotensin II. Each of these injections were a 100uL mixture of angiotensin II and filter 
sterilized saline solution.The blood pressures of these mice were monitored using the CODA tail 
cuff system for 9 days. After analysis of the collected blood pressure data, it was decided that 
100ug of angiotensin II would be used for the mouse trials utilizing direct injections of the drug.  
The injections for the actual trial using the four experimental groups were performed every other 
day. Again, the desired amount of drug was dissolved in 100 uL of filter sterilized saline 
solution. The injections were administered intraperitoneally in the lower left abdominal region of 
the mice as pictured below in figure(4). The blood pressure of the mice was measured on the 
alternate days when the mice were not injected. 
 
 
Figure 4: Intraperitoneal injection technique used on mice.  
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 2.5) Mice Experiments 
In order to experimentally analyze the effects of high serotonin levels on an aortic valve that is 
under high mechanical stress, four experimental groups were needed. Each trial consisted of two 
mice in each of the four groups for a total of eight mice per trial. The control group received 
treatment with filter sterilized saline solution.  
Each trial consisted of 8 C57BL/6J mice divided into the following four experimental groups: 
Control (saline), 5HT, Angiotensin II, and 5HT+Angiotensin II. Each of the groups received 
treatment with the drug corresponding to the name of the group. At the beginning of each trial, 
the amount of each drug to be administered was decided based on whether the trial utilized Alzet 
osmotic pumps or every other day injections to deliver the drug. The quantities of drug delivered 
in each trial are shown in the chart below.  
 Control (Saline) 5HT Angiotensin II 5HT+Angiotensin II 
Osmotic Pump 
Model 2004 
Trial 1  
1x DPBS @ 
.25uL/hr 
0.0025 ng/g/min 0.04ng/g/min Ang II: 0.04 ng/g/min 
5HT: 0.0025 ng/g/min 
Osmotic Pump 
Model 1004 
Trial 2 
1x DPBS@ 
.12 uL/hr 
0.0025 ng/g/min 0.04ng/g/min Ang II: 0.04 ng/g/min 
5HT: 0.0025 ng/g/min 
Osmotic Pump 
Model 1004 
Trial 3 
1x DPBS @ 
.12uL/hr 
0.0025 ng/g/min 0.4ng/g/min Ang II: 0.4 ng/g/min 
5HT: 0.0025 ng/g/min 
Injections 100 uL 1X DPBS 2.13 mg/injection 
in 100uL 
100 ug/injection in 
100 uL 
Ang II: 100ug/injection 
5HT: 2.13mg/injection 
In 100 uL 
 
Table 1: Description of Mouse Trials  
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 Before implantation of the pumps or the beginning of injections, at least one blood pressure 
measurement was performed to establish a baseline pressure for each mouse. Next, eithe r the 
pumps were implanted or the injections began. Blood pressure data was recorded for each animal 
at a minimum of three times per week. For the injection trial, the blood pressure data was always 
recorded on the days on which the mice were not injected. After two weeks, the pressure data 
was analyzed to determine if the drugs had taken the desired effect. If so, the trial was ended on 
day fourteen of treatment. Only trial three was extended to a twenty one day trial. 
When it was time to conclude the trial, the mice were sacrificed by cervical dislocation. 
Immediately, the hearts were dissected out and washed in saline solution. One heart from each 
experimental group was frozen in Tissue-Tex Opitmal Cutting Temperature (O.C.T.) compound 
for histology. The second heart from each group was grossly trimmed down to a small section 
surrounding the aortic valve and immediately placed in a cryovial that was frozen in liquid 
nitrogen. Some of the ventricle was cut away in order to give better resolution in western blot 
data. In each case, the hearts were stored in the -80°C freezer.  
 
2.6) Histology 
In order to analyze the structural condition of the heart and to measure the concentration of 
5HT2A/2B receptors, several histology techniques were implemented.  Examples include H&E 
staining, picrosirius red staining, and immunostaining for 5HT2A/2B receptors along with FGF-1 
and FGF2 receptors. Another undergraduate student that works in Dr. Balachandran’s lab, 
Jessica Morales, was in charge of the histology and the data is part of her research. 
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2.7)Western Blotting 
To test our hypotheses about the response of the aortic valve to the combination of elevated 5HT 
levels and hypertension, several proteins of interest were analyzed via western blotting. As a 
major hypothesis was that the 5HT2A/2B receptors were mechanosensitive, these two receptors 
were quantified by western blotting. Addtionally, to examine the structural health of the valve, 
western blotting for FGF1, FGF2 was completed. B-actin expression was also evaluated via the 
western blot and then used to normalize the expression of the other proteins of interest.   
The western blotting process can be broken down into six distinct sections as follows: 
1. Tissue collection, weighing, and grinding into powder 
2. BCA Protein Assay (Thermo Scientific) 
3. Gel Electrophoresis with 80 ug tissue per lane 
4. Western Blotting Transfer Step 
5. Staining 
6. Imaging 
The gel elctrophoresis and western blotting transfer step were completed with a bio-rad western 
blotting kit. This kit includes the necessary tanks, running buffers, and a PowerPac to use for 
these steps. The gel used was a Bio-Rad Criterion TGX precast gel with twelve lanes. The 
organization of samples and controls in the twelve lane gel electrophoresis is shown below. Each 
sample was run in duplicate to allow for western blotting of multiple proteins from each sample. 
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 1 2 3 4 5 6 7 8 9 10 11 12 
C S1 S2 S3 S4 C C S1 S2 S3 S4 C 
 
Next, the western blotting transfer step was completed. . The organization of the proteins of 
interest on the PVDF membrane are shown below along with the expected moleculat weights of 
each protein. The lines separating the regions denote where cuts were made to allow for separate 
staining of the different regions.  
 
 
 
 
Now that the proteins were on a transfer membrane, they were blocked using Licor blocking 
buffer and a primary antibody incubation was performed for the proteins of interest. The 
secondary antibody was then completed using Licor IR dyes that would allow for infrared 
imaging. The transfer membrane was then imaged using the LICOR Odyssey Infrared Imaging 
system. This system also included software that allowed for quantification of the bands by 
integration intensity.  
 
 
Protein Weight (kDa) 
5HT2A 53-55 
5HT2B 50-55 
FGF-1 15.5 
FGF-2 18/21/24 
FGFR-1 92 
B-actin 42 
FGFR1 
5HT2A, B-actin
FGF1 
5HT2B  
B-actin 
FGF2 
Table 2: Gel Electrophoresis layout 
37 kDa 
75 kDa 
Figure 5: Western blot data and expected protein molecular weight 
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 2.8) Statistics and Analysis 
2.8.1) Blood Pressure Analysis 
. In order to get a good idea of the blood pressure variation over the osmotic pump trials, it was 
decided to analyze and statistically compare both the systolic and diastolic blood pressures at 
three time points in the trial. The first time point was in the preliminary readings, where a 
baseline was established for the blood pressure of each mouse. The second time point was after 
seven days, which is the very middle of each trial except for trial 3. The third point for analysis 
was the last blood pressure taken before the sacrifice of the animals. Because trial three was 
extended to three weeks instead of two, a time point was also included at 21 days for this trial 
only. In the event that a mouse lost the osmotic pump or died, the pressure data was not analyzed 
for this particular mouse. 
The data was grouped by treatment. For example, every preliminary blood pressure reading from 
the saline group was put in one, single column. The same was done for the time points that fell at 
the middle and end of each trial. The mean systolic and diastolic blood pressures were calculated 
as well as the standard error for each column. The same process was repeated for each treatment.  
Additionally, each the data from each time point within each group was statistically compared 
using a one-way ANOVA statistical test using the SigmaPlot software. Occasionally, a one-way 
ANOVA by ranks test was used when the data was not suited for the one-way ANOVA. P values 
are reported in the results section and any P-value less than 0.05 is considered statistically 
significant.  
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 2.8.2) Western Blot Analysis 
Similar to how the blood pressure data was processed, the western blot data was separated by 
treatment group and analyzed. The data from each western blot was consolidated by treatment 
group, and the averages and standard errors were calculated. The data from each group was also 
used to conduct a one-way ANOVA or one-way ANOVA on ranks (if the data was not normally 
distributed) to compare the protein expression between the different groups. For the one-way 
ANOVA, the P-values are reported and the Q-values are reported for the one-way ANOVA on 
ranks.  
The injection dosing trial data and the injection trial data was consolidated and analyzed 
separately, but using the same procedure as for the osmotic pump trials.  
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 3: Results and Discussion 
3.1) Trial Notes 
Osmotic Pump Trial 1 
• Saline group: No complications 
• Angiotensin II group: One mouse lost its pump by day 12 
• 5HT: One mouse lost its pump by day 12 
• Angiotensin II+5HT group: No complications 
• The pumps used in this trial (model 2004) seemed too big for our mouse trial. It appeared 
to stress the mice out, particularly when animal was placed in the animal holder for blood 
pressure readings.  
Osmotic Pump Trial 2 
• Saline group: One mouse lost its pump by day 6 and died on day 11. The other mouse 
had lost its pump by day 9.  
• Angiotensin II group: no complications 
• 5HT Group: One mouse lost its pump by day 9. 
• Angiotensin II+5HT group: One mouse lost its pump by day 9. 
Osmotic Pump Trial 3 
• Angiotensin II+5HT group: One mouse died on day 5 of the trial. 
• No other complications  
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 Osmotic Pump Trial Data 
 
Saline Systolic % Change Diastolic % 
Change 
BaselineDay 7 -5.00 -2.03 
Day 7 Day 14 +5.09 +5.31 
Day 14Day 21 +2.80 -9.34 
Total +2.89 -6.06 
 
 
There was no statistically significant difference in any of the changes of systolic or diastolic 
blood pressures between the analyzed time points in the saline group (P=0.266 for systolic, 
P=0.417 for diastolic). 
The blood pressure of the saline group behaved as expected overall. As depicted in the graph, 
both the systolic and diastolic pressures stayed similar throughout the trial. Again, this was 
expected, since it was the control group that was administered saline solution rather than any 
drug.  
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Figure 6: Osmotic pump trials, saline group blood pressure data. * Denotes statistical significance. 
n= 4 mice 
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Angiotensin II Systolic % Change Systolic 
Q-Value 
Diastolic % 
Change 
Diastolic 
Q-Value 
BaselineDay 7 +6.53 3.147* +6.59 2.621 
Day 7 Day 14 -0.18 0.739 -0.91 0.863 
Day 14Day 21 +4.65 1.027 +5.45 0.886 
Total +11.00 2.945* +11.14 2.284 
 
 
The angiotensin groups did show some significant increase in blood pressure, but not as large of 
an increase as desired. There are several possible explanations for this behavior of the blood 
pressures. One major reason is that the angiotensin II dose was simply too low to elicit the 
desired results. This was certainly the case in the first two osmotic pump trials, as the dose was 
0.04 ng/g/min as opposed to the 0.4 ng/g/min that was used in the third osmotic pump trial. Still, 
the third trial produced results similar to the first two. Another possible explanation would be the 
fact that the pumps did not always stay in the animal to the end or could have potentially been 
damaged or not functioned properly. After the pump is implanted, the researcher loses control of 
the drug delivery process and just has to expect it to work. If it malfunctions, the results could 
easily change.   
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Figure 7: Osmotic pump trials, angiotensin II group blood pressure data. * Denotes statistical significance. 
n= 5 mice 
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5HT Systolic % Change Systolic 
Q-Value 
Diastolic % 
Change 
Diastolic 
P-Value 
BaselineDay 7 -2.50 1.073 -1.97 0.496 
Day 7 Day 14 +8.12 2.499 +9.78 0.004* 
Day 14Day 21 -12.30 4.088* -31.67 <0.001* 
Total -6.68 2.851* -23.86 <0.001* 
 
 
The 5HT group showed some up and down variance for the systolic and diastolic blood pressures 
throughout the trials. While there doesn’t seem to be any clear trend, some change in blood 
pressure can be expected as 5HT is a vasoactive hormone. The data displayed above does not 
affect the hypothesis or the testing of the hypothesis. It does seem that any effect that 5HT had 
on the blood pressure was reduced after 14 days.  
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Figure 8: Osmotic pump trials, 5HT group blood pressure data. * Denotes statistical significance. 
n= 4 mice 
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Angiotensin II + 
5HT 
Systolic % Change Systolic 
Q-Value 
Diastolic % 
Change 
Diastolic 
Q-Value 
BaselineDay 7 +17.63 3.529* +28.90 4.191* 
Day 7 Day 14 -9.79 2.393 -15.09 2.567 
Day 14Day 21 +0.74 0.709 +3.50 1.080 
Total +8.58 1.475 +17.31 2.176 
 
 
This group was the key group to the testing of the hypothesis. It was essential that the mice had 
hypertension as well as were exposed to elevated levels of serotonin. While the mice were 
certainly subjected to increased serotonin levels, the blood pressure data does not reveal the 
marked increase to hypertension that was desired. There are really two plausible explanations for 
this observation. One, the dose of angiotensin II could be too low as mentioned in the analysis of 
the angiotensin II treatment group. The second possible explanation is that there is some 
interplay between angiotensin II and 5HT that prevents the angiotensin II from having its full 
effect. For this reason, it might be the best option to find another method to increase the blood 
pressure or purchase genetically hypertensive mice rather than trying to induce hypertension via 
angiotensin II.  
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Figure 9: Osmotic pump trials, angiotensin II + 5HT group blood pressure data. * Denotes statistical significance. 
n=4 mice 
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 Injection Dosing Trial 
• No complications in this trial 
 
 
100ug Systolic % Change Systolic 
P-Value 
Diastolic % 
Change 
Diastolic 
P-Value 
BaselineDay 6 +14.1 %  0.0984 +16.8% Q 
Day 6 Day 9 +3.6% 0.045* +6.4% Q* 
Total +17.7% 0.045* +23.2% Q* 
 
 
The data from this trial that was used to choose a dose of angiotensin II for the injections shows 
that both the 10 ug and 100 ug doses of angiotensin II are effective. The total changes in systolic 
and diastolic pressure for the 10 ug treatment were 10.9% and 18.3% respectively as outlined 
above in the table. For the 100 ug treatment group the total changes in the systolic and diastolic 
blood pressures were slightly higher at 17.7% and 23.2% respectively. The major difference in 
these two treatments reveals itself in the change between the baseline blood pressure and the 
blood pressure that is measured at day 6. In the 10 ug group, the pressures stayed stable or even 
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10ug Systolic % Change Systolic P Value Diastolic % 
Change 
Diastolic P Value 
BaselineDay 6 +0.09 %  <0.001* -6.8% <0.001* 
Day 6 Day 9 +10.8% .179 +25.1% 0.04* 
Total +10.9% <0.001* +18.3% <0.001* 
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Figure 10: Injection dosing trial blood pressure data. * Denotes statistical significance. n= 3 mice for 
each dose 
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 decreased between the baseline pressure and day 6. However, in the 100 ug group, the effect of 
the angiotensin II seems to be more immediate as the pressure rises noticeably in the first six 
days of the trial. While this change isn’t marked as statistically significant, the P-value is 0.0984, 
which suggests that more trials would make this a statistically significant jump. This immediate 
rise of the blood pressure is what is desired in the short, two-week, trials that were used to test 
the hypothesis. It is necessary for the mice to have hypertension as soon as possible in the two 
weeks so that the study reflects the combination of elevated 5HT levels and hypertension. 
 For this reason, it was decided that the future injection trials would utilize a dose of 100 ug of 
angiotensin II per injection. This trial suggests that the dose should provide the hypertension 
model in the mice that was desired to test the hypothesis.  
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 Injection Trial 
• No complications in this trial 
 
 
 
 
 
According to a one-way ANOVA statistical test, the systolic and diastolic value were not 
significantly different between any of the three time points. For systolic blood pressure the P-
value was 0.892 and for the diastolic blood pressure the P-value was 0.616. This is exactly what 
would be expected from the control group of the experiment. The blood pressure should not 
increase or decrease significantly over the trial from injecting PBS into the mice.  
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BaselineDay 7 +3.8% -4.6% 
Day 7 Day 14 -2.2% +0.2% 
Total +1.5% -4.4% 
Figure 11: Injection trials, saline group blood pressure data. * Denotes statistical significance. 
n=2 mice 
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There was no significant difference in the diastolic blood pressures at the three measured points 
(P=0.22).  Since this was the angiotensin II group, these results do not follow the expected trend. 
The injection dosing trial revealed an increasing blood pressure from injecting this dose of 
angiotensin II every other day. However, this data shows a 13.1% drop in systolic blood pressure 
from the baseline to day 7 and then it rises back up by 12% between day 7 and day 14. The 
increase in systolic and diastolic blood pressure between day 7 and day 14 is expected, but the 
drop in blood pressure was not. One possible explanation for this is that the mice initially 
displayed a higher blood pressure from stress associated with the tail cuff system and having the 
blood pressure measurements taken. As the animals acclimate to this, a drop in pressure could 
occur. The second possible reason that the pressure dropped is related to the timing of the 
injections and blood pressure readings. If each injection only had effect for a short time until the 
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Angiotensin II Systolic % Change Systolic 
P-Value 
Diastolic % 
Change 
BaselineDay 7 -13.1% 0.016* -13.7 
Day 7 Day 14 +12.0% 0.034* +14.3 
Total -1.1% 0.743 +0.7 
Figure 12: Injection trials, angiotensin II group blood pressure data. n= 2 mice 
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 mice could adjust to the raise in angiotensin II, then measuring blood pressure at different times 
on the alternate days could really effect the blood pressure data that is collected. It could also 
potentially explain a decrease in the blood pressure such as the one seen in this data set. 
In order to test if the effectiveness of the angiotensin II injections varies over time, I suggest a 
kinetic study of the angiotensin in the blood of the mouse. If the free level of angiotensin II could 
be monitored over two days following an injection, the action of the drug could be better 
understood. In addition to monitoring the free level of angiotensin II in the blood, it would be 
necessary to monitor the blood pressure every few hours over these two days. If these two 
studies were completed then there would be a good idea of the kinetics of both the drug and the 
blood pressure of the mice following each injection. This could lead to important information 
regarding the timing of blood pressure readings used to collect data for an experimental trial. If 
the blood pressure does vary over the next day or two, it would become essential to measure the 
blood pressure of the mice at the same amount of time after an injection in order to gather 
accurate data.  
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For the 5HT injected mice in this trial, another interesting blood pressure trend was observed. 
The expectation for the 5HT group is to have some variance in blood pressure, but not any huge 
differences one way or another. Previous studies in other labs have reported both increases and 
decreases in blood pressure from 5HT administration to animals. Still, increases of 29.9% and 
41.9% for the systolic and diastolic blood pressures over two weeks seems fairly large. Again, it 
would probably help to perform the blood pressure readings at a set time after the injections to 
ensure consistency. Overall, it would be expected that these results will level out with the 
completion of more injection trials.   
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5HT Systolic % Change Systolic 
Q-Value 
Diastolic % 
Change 
Diastolic 
P-Value 
BaselineDay 7 +4.3% 0.792 +7.0% 0.4 
Day 7 Day 14 +25.6% 3.500* +34.9% <0.001* 
Total +29.9% 4.263* +41.9% <0.001* 
Figure 13: Injection trials, 5HT group blood pressure data. n= 2 mice 
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Angiotensin II+ 
5HT 
Systolic % Change Systolic 
P-Value 
Diastolic % 
Change 
Diastolic 
P-Value 
BaselineDay 7 -14.4% 0.007* -20.5% <0.001* 
Day 7 Day 14 +32.2% <0.001* +53.5% <0.001* 
Total +17.8% 0.008* +32.9% <0.004* 
 
 
 
The same trends that were observed in the angiotensin II group are observed in the group of the 
injection trial. Although the trend is not the expected one, it is good to see that the angiotensin II 
effect seems to take precedence over the effect of the 5HT in regards to blood pressure. The good 
news is that this group did exhibit an overall increase in blood pressure that was significant. This 
data should work well for the testing of the hypothesis. The only desired change is an earlier 
hypertensive state within the two week trial. For this reason, analysis of the angiotensin group as 
outlined in the discussion would probably benefit this group as well.  
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Figure 14: Injection trials, angiotensin II + 5HT group blood pressure data. n= 2 mice 
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 Western Data 
 
1) 5HT2A 
 
 
 
 
 
 
 
 
 
 
 
 
There are no statistically significant differences in the 5HT2A receptor expression between 
the four experimental groups (P=0.282). Still, a trend is visible in the data. As expected, 
the 5HT group exhibits the highest level of 5HT2A receptors. It is noteworthy that the 
angiotensin II + 5HT group does not reveal this same increase in expression of the 
receptor. This could be related to some interplay between the angiotensin II and 5HT. It 
would be interesting to run longer trials and see if the angiotensin II + 5HT group didn’t 
reveal higher expression over time.  
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Figure 15: 5HT2A western blot data. n= 4 western blots,  
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 2) 5HT2B 
 
 
 
 
 
 
 
 
 
 
 
There are no statistically significant differences in the 5HT2B receptor expression between the 
four experimental groups (P=0.476). Again, as expected, the 5HT treated group shows, on 
average, the highest expression of the receptor. Additionally, the angiotensin II + 5HT group 
showed much lower expression of the receptor than the 5HT group similar to the results of 
the 5HT2A receptor. Unfortunately, the 5HT2B receptor did not always appear in western 
blotting. For this reason, more data is certainly needed to outline any trends.  
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Figure 16: 5HT2B western blot data. n= 2 western blots 
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 3) FGF-1 
 
 
 
 
 
                 
 
 
 
 
There are no statistically significant differences in the FGF-1 expression between the four 
experimental groups (P=0.318). The saline, angiotensin II and angiotensin II + 5HT 
groups express roughly the same amount of FGF-1. The 5HT group expressed a higher 
amount of FGF-1 than the control group by 31%. The initial hypothesis was that, as the 
angiotensin II + 5HT group began to act more like a diseased valve, then the amount of 
normal remodeling by FGF-1, and thus the expression of FGF-1 would decrease. Again, 
this would be interesting to watch over a longer trial, but it is important to be able to 
catch this in the beginning in order to suggest any treatment. Furthermore, more data 
needs to be collected to observe any statistically significant trends.  
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Figure 17: FGF-1 western blot data. n= 4 western blots 
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 4) FGF-2 
 
 
 
 
 
 
 
 
 
 
 
 
 
There are no statistically significant differences in the FGF-2 expression between the four 
experimental groups (P=0.172). Similar to the other proteins of interest, there needs to be 
more data collected in order to observe trends or statistically significant data. Much like 
the expectation for FGF-1 expression, the expression of FGF-2 would be expected to 
decrease as the valve began to exhibit pathological conditions. The data above does show 
the lowest amount of FGF-2 expression in the angiotensin II + 5HT group, which does 
line up with the expected results. Still, more data is needed to ensure that the difference is 
not from random variation. 
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Figure 18: FGF-2 western blot data. n=4 western blots 
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 5) FGFR1 
 
 
 
 
 
 
 
 
 
 
 
 
 
There can be no statistical comparison of the FGF-R1 expression as it only showed up in 
the western blot from one trial. Even when it did show up, it is very dim as can be seen 
from figure (19) above. Future experimentation with this project will hopefully reveal 
more data. As the data comes, the same trend is expected as that of FGF-1 and FGF-2.  
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Figure 19: FGF-R1western blot data. n= 1 western blot 
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 4: Conclusions 
A mouse model was successfully established to investigate the effects on the aortic valve in 
subjects with elevated 5HT levels along with cardiovascular hypertension. Based on the results 
of this study, a daily direct injection model is suggested going forward with this project. This 
method, rather than osmotic pumps, reduces complications and allows for dosage adjustment if 
needed during a trial. Additionally, the pumps seemed to make the mice uncomfortable when 
placed in the rodent holders for blood pressure readings. The injection model removes this stress 
and improves the accuracy of the blood pressure measurements. Drug and blood pressure 
kinetics should be analyzed to further improve and confirm the viability of this injection model. 
Long term studies should also be considered to see if the effects become more pronounced over a 
longer time period.  
The western blot data that is gathered from this model shows some trends, but more heart 
samples will be needed for western blotting to validate these trends are statistically significant. 
Additionally, the histology analysis of the heart tissues will either further confirm or reject these 
observed trends.  
Overall, the setup of the animal model was a success. Future studies using this model could 
successfully reveal the mechanism by which elevated 5HT levels can lead to a diseased aortic 
valve when under high mechanical stress. Knowledge of this mechanism could be directly 
applied or used to improve in vitro experimentation used to find a treatment for this type of 
valvular pathology.  
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 Appendix 
Comparing Western Blot Data Between Pump and Injection Trials 
1) 5HT2A 
 
The trends seen in the 5HT2A receptor expression are similar between osmotic pumps and 
injections, but the differences seem to be magnified with the osmotic pump model. Overall, the 
highest expression of the receptor is seen in the 5HT group. The lowest in the osmotic pump trial 
is seen in the 5HT + Ang. II group and in the Ang. II group in the injection trial. As mentioned in 
the western blot analysis before, it is difficult to know why the expression drops so markedly 
between the 5HT group and the 5HT + Ang. II group. This trend should be confirmed with more 
data and should be investigated using genetically hypertensive mice. The fact that there is only 
one western blot using the injection method suggests that more data must be gathered before this 
comparison is finalized. However, it is suggested that the comparison between the two drug 
delivery methods be continued as data continues to be produced by the model.  
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 2) FGF-1 
 
The trends in FGF1 expression do not match up between the injection and osmotic pump trials. 
In the osmotic pump trials, the relative order of expression in the different treatment groups is as 
follows: 5HT + Ang. II < Ang. II < Saline < 5HT. On the other hand, the relative order in the 
injection trials is saline < Ang. II < 5HT< 5HT + Ang. II. These relationships really do not line 
up at all. The expected results would fall more toward the osmotic pump averages as a valve 
turning toward the diseased state would be hypothesized to express a lower amount of FGF1. In 
this model, the group that should be changing to a diseased state would be the 5HT + Ang. II 
group. Certainly, as the sample sizes are only between 1 and 2, more data needs to be acquired 
before a good comparison can be made between the two drug delivery methods with regard to 
FGF-1 expression.  
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 3) FGF-2 
 
Similar to the trends seen in FGF-1, the FGF-2 trends do not match up between the osmotic 
pump trial western blots and the injection trial western blots. The hypothesis would be to see the 
lowest level of expression in the 5HT + Ang. II group as the valve would likely not be 
restructuring normally if it were progressing to a diseased state. Still, in a two week trial, it is 
difficult to determine exactly how and to what degree the FGF-2 expression should change. For 
this reason, a major suggestion would be to investigate the variance of the FGF-2 expression 
over a longer time frame. This would ensure that the valve had enough time to begin exhibiting 
the behavior of a diseased valve. Much like the FGF-1 expression, the osmotic pumps seem to 
show an expression pattern more similar to the expected pattern than the injection trials. Still, 
more data is required for a strong comparison to be made between the two different drug delivery 
models.  
*The other proteins analyzed in the western blot data that were not compared here were either 
not seen in the injection or osmotic pump trials. Therefore, there was no way to compare the two 
drug delivery methods.   
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 Osmotic Pump Loading Protocol 
1. Prepare desired concentrations of different drugs 
a. For 5HT and Angiotensin II, the desired concentrations can be calculated on excel. Access 
the sheet by:  Research ProjectsMouse StudiesDrug Concentration 
b. Input parameters at the top of the sheet and the amount of PBS and drug needed to fill the 
pump will be calculated. 
c. Make sure to prepare extra solution since some will inevitably be lost.  
2. Weigh the empty pump and flow moderator. 
3. Using a syringe and the provided filling tube, draw up the desired amount of drug and remove any air 
bubbles.  
4. Holding the pump with the opening facing up, insert the filling tube through the opening at the top of 
the pump until it can go no further. 
5. Slowly empty the syringe, maintaining the upright position of the pump. When the solution appears at 
the outlet, stop filling and carefully remove the tube. 
6. Wipe off the excess solution and insert the flow moderator until the cap is flush with the top of the 
pump.  
7. Weigh the filled pump with the flow moderator in place.  
a. For most solutions, the weight change in milligrams is approximately the same as the volume 
of solution you have added in microliters.  
8. To prime the pumps, place them in saline preferably for 24-48 hours at 37° C. Make sure to label the 
containers with PBS to ensure that you remember which pump is which. 
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 Blood Pressure Measurement and Injection Protocols 
1. Pull out the two rolling carts and place side by side with the coda control box facing the big 
table. 
2. Place the heating platform on the large cart 
3. Plug in the power strip and then plug the adapters into the coda control box and the heating 
platform. Turn the heating platform to level 3 and 1.5 for the time. Cover the heating platform 
with the warming cover. 
4. At this point, I would advise putting the first two mice in the holders and putting them on the 
heating platform, under the cover to let them warm up.  
5. Attach the tail cuffs to the control box. One of the bags containing the cuffs is marked with a 
“1.” This is the cuff that goes with channel one. The other goes with channel two. 
6. Slide the tail cuffs onto the mice and make sure that the O-ring is closest to the body of the 
mouse. Also make sure you note the channel number that you are hooking the mice up to. 
Generally, I hook the lower number mouse up to channel one, and the higher number to 
channel two. Again, leave the mice under the cover. 
7. Now place the next two subject mice in the holders and place them under the cover so that they 
can begin warming.  
8. Make sure and plug the USB cord into the computer and open the CODA software.  
9. Press “new session wizard”(looks like a blank page in upper left corner), pick the appropriate 
trial(#4 in this case), select the mice you have (guide in red notebook), leave the settings as they 
are, and then you should see the “begin” option.  
10. For the first two mice, I generally allow another 5 minutes for relaxation and warming. 
11. Press begin. 
12.  When the experiment ends, the data will pop up and you should click “save to excel.” Save it 
somewhere that you can find it again. 
13. Repeat for all the mice. You shouldn’t have to wait on the next groups to warm since they have 
been on the platform for a while by the time you need them. Still, I generally hook them up to 
the tail cuff, then take out the previous two mice from the holders and place the next two mice 
in the holders before beginning the next experiment.  
14. After you have measured the pressures of all the mice, clean everything thoroughly with 70% 
alcohol and paper towels. 
15. Disconnect the tail cuffs and place them in the appropriate bags.  
16. Unplug everything and put it up on the carts like you found it.  
Injections: 
We have stock of 10-3 M angiotensin and 0.1 M serotonin. We also have saline. For each of these 
experimental groups you simply inject 100uL to each specimen of the mentioned drugs. 
For the mixture, add 10uL of 10-2M angiotensin per 100uL of 0.1M serotonin. This gives the amount of 
each drug necessary. In general, make more than you need as exactly 220uL will not be enough with the 
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 syringes. (I generally try 250uL of serotonin and 25uL of angiotensin. If you are careful with the 
injections, this is enough.)  
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